Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

LONDON, GREATER LONDON, UNITED KINGDOM, February 25, 2025 /EINPresswire / -- How Has The Gastric Cancer Market Size Evolved In Recent Years And What Is Its Growth Potential? The gastric cancer ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Carcinoid tumours, another form of cancer that tends to grow slowly ... typically start in the digestive system – including the stomach, appendix, small intestine, colon, rectum – or in ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Endoscopic submucosal dissection or ESD is an advanced endoscopic procedure that allows for the complete removal of early tumors and cancers of the esophagus, stomach and rectum. In 2015, trained ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...